{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T09:00:04Z","timestamp":1767085204479,"version":"3.40.5"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HLA"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm treated with tyrosine kinase inhibitors (TKIs). Although survival rates have improved, response to these treatments is highly heterogeneous. Variations in response rates may be due to different causes such as, treatment adherence, mutations in the BCR\u2010ABL1 gene, clonal evolution and amplification of the BCR\u2010ABL1 gene, but innate immune response is also considered to play a very important role and, specifically, NK cell activity through their receptors and ligands, could be determinant. The aim of this retrospective study was to explore the role of different activating and inhibiting KIR genes as well as the activating NKG2D receptor, present in NK cells, and also their respective ligands, HLA\u2010A, \u2010B, \u2010C, \u2010G, \u2010F, MICA and MICB, in the progression of 190 patients with CML and treated at two hospitals from Barcelona between 2000 and 2019. Early molecular response (EMR), major molecular response (MMR) or MR3.0 and deep molecular response (DMR) or MR4.0 were correlated. As control samples, healthy donors from the Barcelona Blood Bank were analyzed. The presence of KIR2DL2\/KIR2DS2 was associated with the achievement of EMR, MR3.0, and MR4.0. Carriers of the higher expression NKG2D variant and <jats:italic>MICA*009:01<\/jats:italic> were also likely to achieve molecular response (MR). The most remarkable difference between CML patients and controls was a higher frequency of the lower expression NKG2D variant in CML patients. In summary, our results showed that activating NK receptor phenotypes might help to achieve MR and DMR in CML patients treated with TKIs although confirmatory studies are necessary.<\/jats:p>","DOI":"10.1111\/tan.14515","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T04:33:53Z","timestamp":1639802033000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia"],"prefix":"10.1111","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-5077","authenticated-orcid":false,"given":"Laia","family":"Closa","sequence":"first","affiliation":[{"name":"Histocompatibility and Immunogenetics Laboratory Blood and Tissue Bank  Barcelona Spain"},{"name":"Transfusional Medicine Group Vall d'Hebron Research Institute\u2010Autonomous University of Barcelona (VHIR\u2010UAB)  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[{"name":"Department of Hematology Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Aut\u00f2noma de Barcelona  Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[{"name":"Department of Hematology Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Aut\u00f2noma de Barcelona  Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Estrada","sequence":"additional","affiliation":[{"name":"Department of Hematology Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Aut\u00f2noma de Barcelona  Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Hematopathology Section Hospital Clinic, IDIBAPS, CIBERONC  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Herrero","sequence":"additional","affiliation":[{"name":"Histocompatibility and Immunogenetics Laboratory Blood and Tissue Bank  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-4945","authenticated-orcid":false,"given":"Francisco","family":"Vidal","sequence":"additional","affiliation":[{"name":"Transfusional Medicine Group Vall d'Hebron Research Institute\u2010Autonomous University of Barcelona (VHIR\u2010UAB)  Barcelona Spain"},{"name":"Congenital Coagulopathy Laboratory Blood and Tissue Bank  Barcelona Spain"},{"name":"CIBER of Cardiovascular Diseases  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Alvarez\u2010Larr\u00e1n","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital Clinic, Institut de Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Caro","sequence":"additional","affiliation":[{"name":"Department of Immunology Hospital Cl\u00ednic  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0449-7"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0958-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046636"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1172"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.12262"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403525"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.180"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.07.007"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5428.727"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genom.7.080505.115726"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80394-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199912150-00024"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2001.1810113.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-137521"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.8.5222"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425089"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3513"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00258"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2294-1"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(01)76018-X"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1115-8_5"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/tan.13754","article-title":"Distribution of human killer cell immunoglobulin\u2010like receptors and ligands among blood donors of Catalonia","volume":"95","author":"Closa L","year":"2019","journal-title":"HLA"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.14221"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw829"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02991"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.009134"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.028"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-077438"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/319675a0"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201238598"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.360"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2013.01.008"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0462"},{"issue":"4","key":"e_1_2_8_39_1","first-page":"238","article-title":"Certain killer immunoglobulin\u2010like receptor (KIR)\/KIR HLA class I ligand genotypes influence natural killer antitumor activity in myelogenous leukemia but not in acute lymphoblastic leukemia: a case control leukemia association study","volume":"36","author":"Varbanova VP","year":"2019","journal-title":"Turkish J Haematol"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2009.01235.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.267"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231977"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00193"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003802340"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075005"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437558"}],"container-title":["HLA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tan.14515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tan.14515","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tan.14515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:20:59Z","timestamp":1692976859000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tan.14515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/tan.14515"],"URL":"https:\/\/doi.org\/10.1111\/tan.14515","archive":["Portico"],"relation":{},"ISSN":["2059-2302","2059-2310"],"issn-type":[{"type":"print","value":"2059-2302"},{"type":"electronic","value":"2059-2310"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"2021-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}